Topic

SGLT2 Inhibitor

Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin — SGLT2 inhibitor access, formulary placement, IRA pricing, and generic entry.

3 articles·Lives underPricing & Access Specialty·Last updated 2026-05-18

Pricing & Access· May 18, 2026 · 11 min read

Jardiance vs Farxiga: label, access, and payer coverage compared

Jardiance (empagliflozin) and Farxiga (dapagliflozin) are the two most prescribed SGLT2 inhibitors in the US, each with landmark cardiovascular and kidney outcome data....

By Ran Chen#SGLT2 Inhibitor #Payer Policy #Coverage Access

Pricing & Access· May 17, 2026 · 10 min read

Farxiga coverage guide: formulary, prior authorization, and what access teams should know

Farxiga (dapagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. This guide maps FDA indications, dosing, formulary...

By Ran Chen#SGLT2 Inhibitor #Formulary #Prior Authorization

Pricing & Access· May 17, 2026 · 9 min read

Jardiance coverage guide: formulary, prior authorization, and what access teams should know

Jardiance (empagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. This guide maps FDA indications, dosing,...

By Ran Chen#SGLT2 Inhibitor #Formulary #Prior Authorization